Trial Profile
PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2020
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms PROVIDE-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 30 Mar 2020 Results (n= 270) presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
- 11 Dec 2019 Status changed from recruiting to completed.
- 10 Jan 2019 Planned End Date changed from 17 Jun 2019 to 1 Jul 2019.